pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study
暂无分享,去创建一个
[1] J. Albrecht,et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy , 2010, Hepatology.
[2] A. Cheng-Lai,et al. Pitavastatin: A New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia , 2010, Cardiology in review.
[3] R. Chung,et al. An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells , 2010, Hepatology.
[4] R. Chung,et al. New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells , 2010, Hepatology.
[5] Yoshiyuki Suzuki,et al. An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads , 2009, Intervirology.
[6] C. Aston,et al. Fluvastatin Inhibits Hepatitis C Replication in Humans , 2008, The American Journal of Gastroenterology.
[7] T. Asselah,et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. , 2008, Gastroenterology.
[8] R. Chung,et al. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial , 2007, Hepatology.
[9] K. Naka,et al. Different anti‐HCV profiles of statins and their potential for combination therapy with interferon , 2006, Hepatology.
[10] R. Andrade,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.
[11] N. Kato,et al. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. , 2007, Journal of pharmacological sciences.